|Day Low/High||0.79 / 0.94|
|52 Wk Low/High||0.71 / 6.74|
It feels like these companies are casting a wide net, but it makes sense to file at the beginning of this mushroom mania.
Dealmaking is going strong and looks set to continue as mental health becomes a key investment theme going forward.
With the state of Oregon's move to decriminalize drugs, the stigma around compounds like ketamine is lessening.
It seems depression may be the condition that propels psychedelics to be accepted.